Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAB-16
- Development stage
- Preclinical
- Lead developer
- Brigham and Women's Hospital
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
DAB-16 is a specific dendrimer-linked nitroxide, a type of nanoparticle, developed as a positively charged magnetic resonance imaging (MRI) contrast agent for cartilage. It is composed of a polypropyleneimine (DAB) dendrimer with 16 nitroxide groups attached to its terminal amines. The drug is designed to assess cartilage matrix compositional alterations, particularly in osteoarthritis, by diffusing preferentially into cartilage due to its positive charge and attraction to the negatively charged glycosaminoglycans (GAGs) within the cartilage matrix. This diffusion leads to enhanced MRI signal intensity by interacting with protons in water, allowing for better visualization and assessment of cartilage health.
02
Targets
Gag (HIV-1 Gag polyprotein)H (Histamine receptors)
Beyond the preview
Go deeper on DAB-16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAB-16.